Health Catalyst (NASDAQ:HCAT) Releases Earnings Results, Misses Expectations By $0.03 EPS

Health Catalyst (NASDAQ:HCAT) released its earnings results on Wednesday. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03), Briefing.com reports. Health Catalyst had a negative return on equity of 7.49% and a negative net margin of 26.20%. The business had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the prior year, the company earned ($0.22) earnings per share. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. Health Catalyst updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.

Health Catalyst Price Performance

HCAT traded down $0.62 during midday trading on Friday, hitting $8.24. 674,743 shares of the company traded hands, compared to its average volume of 485,899. The company’s 50-day moving average is $8.07 and its 200 day moving average is $7.14. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $11.41.

Wall Street Analysts Forecast Growth

HCAT has been the topic of a number of recent research reports. Piper Sandler cut their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Stephens cut their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Royal Bank of Canada lifted their price objective on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Finally, Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.64.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,396 shares of company stock worth $266,280 over the last three months. 2.50% of the stock is currently owned by company insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.